Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1
OBR Daily - Our Oncology Focused E-News Service

Register for OBR daily



Warning: Missing argument 1 for showSidebarBanner(), called in /home2/don/public_html/sidebar_obrgreen.php on line 38 and defined in /home2/don/public_html/include/banners.php on line 243
FM_ROS_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CERU $5.71 0.6699 +13.29%
SNSS $2.34 0.0900 +4.00%
IDRA $3.11 0.1100 +3.67%
CBMG $15.83 0.4896 +3.19%
GLYC $9.68 0.2800 +2.98%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

APRI $1.18 -0.1200 -9.23%
CPXX $1.70 -0.1200 -6.59%
GALT $3.97 -0.2800 -6.59%
MACK $9.16 -0.6000 -6.15%
ONTY $1.75 -0.1100 -5.91%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Epigenetic Study Reveals New Insights Into Breast Cancer

(ESMO) May 5, 2011 - The most comprehensive analysis yet of the epigenetic modifications present in breast cancer has revealed potentially important new ways to detect and treat the disease, Belgian researchers have reported.
read press release 



About the Premarin Study and Breast Cancer

(ACP Internist Blog) May 4, 2011 - This week a paper came out in JAMA showing a surprising reduction in breast cancer cases among women who had hysterectomies and then took Premarin, an estrogen-only remedy compounded from steroids in horses' urine.
read article 



Strong Evidence Supports Prognostic Value of Circulating Tumor Cells in Breast Cancer

(ESMO) May 5, 2011 - French researchers have reported the strongest proof yet that evidence of ‘circulating tumor cells’ found in samples of a patient’s blood is strongly linked to poor outcomes such as a short time to disease progression.
read press release 



Researcher Maps Far-Reaching Effects of Estrogen Signaling in Breast Cancer Cells

(UT Southwestern) May 5, 2011 - A UT Southwestern Medical Center researcher has identified the most comprehensive measurement to date of estrogen’s effect on breast cancer cells, showing for the first time how immediate and extensive the effect is.
read press release 



FDA Approves Test to Identify Candidates for Breast Cancer Drug

(NCI Cancer Bulletin) May 3, 2011 - The Food and Drug Administration (FDA) has approved a genetic test that doctors can use to help identify women with breast cancer who have extra copies of the HER2 gene and therefore may benefit from the drug trastuzumab (Herceptin).
read article 



Einstein Researchers Find Key Gene in Childhood Cancer

(Albert Einstein) May 5, 2011 - There are no effective treatments for rhabdoid tumors – aggressive childhood cancers that usually strike children under three years old and affect the brain or kidneys.
read press release 



Childhood Cancer Survivors Are at Increased Risk for Ongoing Post-Therapy GI Complications

(AGA) May 4, 2011 - Patients who received therapy for cancer during childhood have an increased risk of developing gastrointestinal (GI) complications later in life, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. Compared with their siblings, cancer survivors had an increased risk of late-onset complications of the upper GI tract, lower GI tract and liver.
read press release 



Celgene's Revlimid Extends Life in Cancer Trial

(Reuters) May 5, 2011 - Celgene Corp's cancer drug, Revlimid, significantly extended the lives of patients with multiple myeloma who took the drug as a maintenance therapy following a stem cell transplant.
read article 



Supplements Don't Prevent Prostate Cancer: Study

(Reuters) May 4, 2011 - A new study deflates hopes that certain nutritional supplements could stave off prostate cancer, the second most common cancer in men.
read article 



Supplements Don't Prevent Prostate Cancer: Study

(Reuters) May 4, 2011 - A new study deflates hopes that certain nutritional supplements could stave off prostate cancer, the second most common cancer in men.
read article 



Senate Bill Introduced to Correct Medicare Drug Reimbursement

(Yahoo! Finance) May 5, 2011 - U.S. Senator Pat Roberts (R-KS) and lead co-sponsor U.S. Senator Debbie Stabenow (D-MI) have introduced S. 733, a bipartisan bill designed to address a Medicare reimbursement flaw.
read article 



Perspective: Listening to Provenge — What a Costly Cancer Treatment Says About Future Medicare Policy

(NEJM) May 5, 2011 - In April 2010, the Food and Drug Administration (FDA) approved sipuleucel-T (Provenge), a novel cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castration-resistant (hormone-refractory) prostate cancer.
read article 



Swedish Study Finds Surgery For Prostate Cancer Better Than Waiting

(NPR's Health Blog) May 4, 2011 - A Swedish study suggests that radical prostatectomy — complete removal of the prostate gland — is better than "watchful waiting" for the treatment of younger men with low-risk prostate cancer.
read article 



Novartis: We're Paying for Reform Without Seeing Benefits Yet

(CNNMoney/Fortune) May 3, 2011 - Swiss drug maker Novartis AG is facing tough competition from generics as several of its key drugs -- namely, bestseller Diovan for hypertension -- begin to lose patent protection in 2012.
read article 



Pfizer’s Read Reviews Units With $18.3 Billion in Revenue

(Bloomberg) May 3, 2011 - Pfizer Inc. Chief Executive Officer Ian Read said he is reviewing the possible sale or spinoff of four divisions with $18.3 billion in annual revenue, led by the company’s third-biggest unit, established products.
read article 



Novartis: New Analysis Highlights Safety Of Lucentis

(NASDAQ/Dow Jones Newswires) May 4, 2011 - Novartis AG Wednesday said a new analysis undertaken by Johns Hopkins University highlights the safety of the use of eye medicine Lucentis.
read article 



FDA, FTC Seek To End Sales Of Unproven STD-Treatment Drugs

(Wall Street Journal) May 3, 2011 - Halting the sale of products that make unproven claims of treating or preventing sexually transmitted diseases is the goal of a joint effort by the U.S. Food and Drug Administration and Federal Trade Commission.
read article (paid subscription required) 



FTC’s Leibowitz Says Rising Generic Drug Deals Hurt Consumers, Need Limits

(Bloomberg) May 4, 2011 - The U.S. Federal Trade Commission said drug-company deals that delayed the introduction of cheaper generic medicines rose 63 percent last year as the agency presses Congress and the courts to limit the settlements.
read article 



Ted Forstmann Being Treated for Brain Cancer

(FOXBusiness) May 3, 2011 - Theodore J. Forstmann has been in many corporate battles over the past four decades as one of Wall Street’s premier deal makers, but now he finds himself in what may be the biggest battle of his life.
read article 



Nine Physicians Associated with Sarah Cannon Research Institute Named to Best Doctors List

(SCRI) May 3, 2011 - Nine Tennessee physicians affiliated with the Sarah Cannon Research Institute (SCRI) were chosen by fellow physicians as Best Doctors in America for 2011-2012.
read press release 



Via Oncology Pathways Now Incorporate Advance Care Planning Decision Support

(Yahoo! Finance) May 4, 2011 - The most recent release of Via Oncology Pathways from D3 Oncology Solutions (D3) now includes decision support for advance care planning to encourage early discussions between oncologists and their patients about the disease, treatment intent and likely outcomes.
read article 



Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer

(NCI Cancer Bulletin) May 3, 2011 - Researchers have developed a benefit-risk index to help guide decisions on whether postmenopausal women at increased risk of developing breast cancer should take raloxifene or tamoxifen to reduce that risk.
read article 



Design Dilemma: The Debate Over Using Placebos in Cancer Clinical Trials

(NCI Cancer Bulletin) May 3, 2011 - Ask a clinical researcher in almost any field except cancer for the “gold standard” of assessing the effectiveness of a new therapeutic drug and you will probably get the same answer: a randomized double-blinded placebo-controlled trial.
read article 



2011 ASCO Annual Meeting—The Front Line in the Fight Against Cancer

(ASCO Connection Magazine) April 2011 - June 3-7, oncology professionals from across the globe will gather at McCormick Place in Chicago, Illinois, to review the latest scientific data, examine new technologies, and connect (or re-connect) with colleagues. Registration, housing, and preliminary session information are available online at chicago2011.asco.org.
read article 



Oxford BioMedica Grants Partner Pfizer Diagnostic Rights to 5T4 Tumor Antigen

(GEN News) May 4, 2011 - Oxford BioMedica has expanded its 5T4 tumor antigen therapeutics collaboration with Pfizer by granting the latter nonexclusive rights to the diagnostic use of antibodies against the antigen and an option to commercialize a 5T4-based diagnostic.
read article